Kymera Therapeutics, Inc (KYMR)

Etorro trading 970x250
Kymera Therapeutics, Inc (KYMR) Logo

About Kymera Therapeutics, Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts. Address: 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472

Kymera Therapeutics, Inc News and around…

Latest news about Kymera Therapeutics, Inc (KYMR) common stock and company :

Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
17 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET. Kymera’s R&D Day will include presentations from Nello Mainolfi, PhD, Co-Founder, President and CEO; Jared Gollo

Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
12 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually. The results reveal Kymera’s potent and s

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Tops Revenue Estimates
10 Nov, 2021 Yahoo! Finance

Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of -64.71% and 0.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kymera Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Business Update
10 Nov, 2021 Yahoo! Finance

Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines FDA clearance of Investigational New Drug Application for first-in-class STAT3 degrader, KT-333R&D Day Webinar scheduled for December 16, 2021, with first disclosures of KT-474 Multiple Ascending Dose data, new degrader programs in development and new platf

Kymera Therapeutics (NASDAQ:KYMR) shareholder returns have been respectable, earning 48% in 1 year
08 Nov, 2021 Yahoo! Finance

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...

Kymera Therapeutics to Present New Preclinical Data on STAT3 Degraders at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting and the 63rd American Society of Hematology (ASH) Annual Meeting
04 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually, and at the

Notable Kymera Therapeutics Insider Trades $3.6M In Company Stock
03 Nov, 2021 Yahoo! Finance

Jared Gollob, Chief Medical Officer at Kymera Therapeutics (NASDAQ:KYMR), made a large buy and sell of company shares on November 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Jared Gollob exercised options to purchase 39,603 Kymera Therapeutics shares at prices ranging from $1.31 to $2.08 per share for a total of $66,974 on November 2. They then sold their shares on multiple transactions in the open market. They sol

Stocks To Watch: Kymera Therapeutics Sees RS Rating Jump To 82
02 Nov, 2021 FinancialContent

Kymera Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 72 to 82.

Kymera Therapeutics to Participate in Upcoming Fourth Quarter Investor Conferences
01 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in several upcoming virtual investor conferences: UBS: Panel discussion: “TPD from Concept to Clinic: What Have We Learned So Far From Clinical Data?” on November 1, 2021 at 11:00 a.m. ET.Credit Suisse 30th Annual

Stocks Generating Improved Relative Strength: Kymera Therapeutics
29 Oct, 2021 FinancialContent

A Relative Strength Rating upgrade for Kymera Therapeutics shows improving technical performance. Will it continue?

Kymera Therapeutics Presents Positive Data Demonstrating Robust IRAK4 Degradation and First Proof-of-Biology with Inhibition of Cytokine Induction from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers
27 Oct, 2021 Yahoo! Finance

Mean IRAK4 degradation of up to 96% in PBMC and up to 97% inhibition of ex vivo induction of multiple proinflammatory cytokines observed, suggesting potential for broad anti-inflammatory effect KT-474 was well-tolerated at all dose levels Kymera to present results at 4th Annual Targeted Protein Degradation Summit today at 8:30 a.m. ET Kymera to host conference call today at 10:30 a.m. ET WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stag

10 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
27 Oct, 2021 Yahoo! Finance

In this article, we examined Mark Lampert’s investment philosophy and decades of experience in the biotechnology space. We also reviewed 10 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund. You can skip our detailed discussion and jump directly to 5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund. Mark […]

Sum Up The Parts: FYX Could Be Worth $108
26 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Small Cap Core AlphaDEX Fund ETF (FYX), we found that the implied analyst target price for the ETF based upon its underlying holdings is $107.79 per unit.

Hedge Funds Are Betting On Kymera Therapeutics, Inc. (KYMR)
25 Oct, 2021 Yahoo! Finance

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious towards the current bull run since March, 2020 and hedging or reducing many of their long positions. Some fund managers are betting on Dow […]

Kymera to Hold Webcast and Conference Call Discussing Data from its KT-474 Phase 1 Trial to Be Presented at the 4th Annual Targeted Protein Degradation Summit on October 27th
20 Oct, 2021 Yahoo! Finance

WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will hold a webcast and conference call to review the data from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 trial in healthy volunteers to be presented at the 4th Annual Targeted Protein Degradation Summit o

Kymera Therapeutics to Present Pharmacokinetic and Pharmacodynamic Data, including Cytokines, from the Single Ascending Dose Portion of KT-474 Phase 1 Trial in Healthy Volunteers at the 4th Annual Targeted Protein Degradation Summit
13 Oct, 2021 Yahoo! Finance

WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will be giving multiple presentations at the 4th Annual Targeted Protein Degradation Summit, taking place from October 26 - 29, 2021. A Keynote Plenary Session presentation will include safety, pharmacokinetic (PK) and pharma

Where Kymera Therapeutics Stands With Analysts
30 Sep, 2021 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are ...

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

AbCellera, Kymera and Diamondback Move in After-Hours
16 Sep, 2021 Yahoo! Finance

Among stocks seeing big moves in after-hours trading Thursday, AbCellera Biologics gained after saying it won emergency use authorization from the Food and Drug Administration for a treatment of people who've been exposed to COVID. The company said its bamlanivimab drug can now be used in combination with another drug called etesevimab "to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination." The move "provides a way to protect the significant number of people who, because of their situational exposure risk or medical condition, remain vulnerable to COVID-19," said Carl Hansen, CEO and president of AbCellera, in a statement.

Noteworthy Monday Option Activity: UNFI, ECHO, KYMR
13 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in United Natural Foods Inc. (UNFI), where a total volume of 4,637 contracts has been traded thus far today, a contract volume which is representative of approximately 463,700 underlying shares (given that every 1 contract represents 100 underlying shares)..

Kymera Therapeutics to Present at Upcoming September Investor Conferences
02 Sep, 2021 FinancialContent
Kymera Therapeutics Shows Rising Price Performance With Jump To 87 RS Rating
24 Aug, 2021 FinancialContent

Kymera Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Stocks With Rising Relative Strength: Kymera Therapeutics
18 Aug, 2021 FinancialContent

Kymera Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Time To Worry? Analysts Are Downgrading Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook
08 Aug, 2021 Yahoo! Finance

Today is shaping up negative for Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) shareholders, with the analysts delivering a...

Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
06 Aug, 2021 FinancialContent
Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
29 Jul, 2021 FinancialContent
Is KYMR Stock A Buy or Sell?
28 Jul, 2021 Yahoo! Finance

In this article we will analyze whether Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead […]

4 Trending Biotech Stocks To Watch This Week
20 Jul, 2021 FinancialContent
Kymera Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Threshold
20 Jul, 2021 FinancialContent

A Relative Strength Rating upgrade for Kymera Therapeutics shows improving technical performance.

Kymera Therapeutics, Inc (KYMR) is a NASDAQ Common Stock listed in , ,

970x250